CRISPR Therapeutics rated Buy with $64.58 target, driven by CASGEVY sales and strong gene therapy pipeline.

CRISPR Therapeutics (CRSP) is rated Buy with a 12-month price target of $64.58, supported by growing commercial sales of CASGEVY and a promising pipeline of gene therapies. CASGEVY's increasing patient treatments and revenue growth offer a near-term path to profitability. The company’s in vivo cardiovascular therapies, including CTX310 and CTX320/321, target large underserved markets with innovative one-time gene treatments. With approximately $2.5 billion in cash and disciplined capital management, CRSP presents an attractive risk/reward profile at its current valuation.